Panion & Bf Biotech (TPE:1760) Beneish M-Score: -2.72 (As of Jun. 26, 2026)


TPE:1760 Panion & Bf Biotech Inc TPE:1760
74 GF Score
Price NT$61.00
GF Value NT$95.99
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Panion & Bf Biotech Beneish M-Score?

Panion & Bf Biotech TPE:1760 -0.65% 74 Beneish M-Score is -2.72 as of Jun. 26, 2026. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$95.99 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Panion & Bf Biotech ranks better than 65.82% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.72 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Panion & Bf Biotech's Beneish M-Score or its related term are showing as below:

TPE:1760' s Beneish M-Score Range Over the Past 10 Years
Min: -3   Med: -2.67   Max: -1.56
Current: -2.72

During the past 13 years, the highest Beneish M-Score of Panion & Bf Biotech was -1.56. The lowest was -3.00. And the median was -2.67.


Panion & Bf Biotech Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Panion & Bf Biotech's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panion & Bf Biotech Beneish M-Score Chart

Panion & Bf Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.86 -3.00 -2.67 -2.90 -2.72

Panion & Bf Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.90 -3.02 -2.96 -2.85 -2.72

TPE:1760 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Panion & Bf Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panion & Bf Biotech Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panion & Bf Biotech's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Panion & Bf Biotech's Beneish M-Score falls into.


TPE:1760
74GF Score
Panion & Bf Biotech Inc TPE:1760
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panion & Bf Biotech Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Panion & Bf Biotech for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9769+0.528 * 0.9742+0.404 * 0.798+0.892 * 1.0166+0.115 * 1.2231
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9749+4.679 * -0.037005-0.327 * 0.9831
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$365 Mil.
Revenue was 546.139 + 531.947 + 503.774 + 481.532 = NT$2,063 Mil.
Gross Profit was 285.903 + 300.286 + 268.61 + 262.052 = NT$1,117 Mil.
Total Current Assets was NT$1,467 Mil.
Total Assets was NT$3,227 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,693 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$138 Mil.
Selling, General, & Admin. Expense(SGA) was NT$613 Mil.
Total Current Liabilities was NT$1,010 Mil.
Long-Term Debt & Capital Lease Obligation was NT$158 Mil.
Net Income was 48.619 + 75.354 + 37.996 + 28.2 = NT$190 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 126.851 + 73.31 + 76.195 + 33.215 = NT$310 Mil.
Total Receivables was NT$368 Mil.
Revenue was 522.539 + 501.205 + 506.416 + 499.485 = NT$2,030 Mil.
Gross Profit was 265.267 + 258.927 + 265.942 + 280.136 = NT$1,070 Mil.
Total Current Assets was NT$1,510 Mil.
Total Assets was NT$3,208 Mil.
Property, Plant and Equipment(Net PPE) was NT$1,614 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$164 Mil.
Selling, General, & Admin. Expense(SGA) was NT$618 Mil.
Total Current Liabilities was NT$1,027 Mil.
Long-Term Debt & Capital Lease Obligation was NT$153 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(365.353 / 2063.392) / (367.889 / 2029.645)
=0.177064 / 0.181258
=0.9769

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1070.272 / 2029.645) / (1116.851 / 2063.392)
=0.52732 / 0.541269
=0.9742

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1466.825 + 1692.726) / 3226.687) / (1 - (1510.457 + 1613.903) / 3208.005)
=0.020806 / 0.026074
=0.798

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2063.392 / 2029.645
=1.0166

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(164.424 / (164.424 + 1613.903)) / (138.419 / (138.419 + 1692.726))
=0.09246 / 0.075592
=1.2231

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(612.693 / 2063.392) / (618.215 / 2029.645)
=0.296935 / 0.304593
=0.9749

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((157.912 + 1009.777) / 3226.687) / ((153.372 + 1027.468) / 3208.005)
=0.361885 / 0.368092
=0.9831

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(190.169 - 0 - 309.571) / 3226.687
=-0.037005

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Panion & Bf Biotech has a M-score of -2.72 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.72 mean?
Panion & Bf Biotech (TPE:1760) has a Beneish M-Score of -2.72 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Panion & Bf Biotech and its competitors. According to the industry distribution chart, Panion & Bf Biotech ranks #284 out of 831 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Panion & Bf Biotech's Beneish M-Score too high?
Panion & Bf Biotech's current Beneish M-Score is -2.72. Based on the distribution chart, Panion & Bf Biotech ranks #284 out of 831 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panion & Bf Biotech ranks #284 out of 831 companies for Beneish M-Score. This puts Panion & Bf Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Panion & Bf Biotech and its competitors. Panion & Bf Biotech's current Beneish M-Score is -2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$95.99, compared to a current price of NT$61.00 — trading 36.5% below its estimated fair value. The current Beneish M-Score is -2.72. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Beneish M-Score is -2.72 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?

Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued. The current stock price of NT$61.00 is trading 36.5% below its estimated GF Value™ of NT$95.99. GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1760:

  • Beneish M-Score: -2.72
  • GF Value™: NT$95.99 vs. price of NT$61.00 (36.5% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Panion & Bf Biotech Business Description

Address No. 3, Park Street, 16th Floor, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score

Get the complete analysis for TPE:1760

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$61.00
Price
NT$95.99
GF Value